NovoCure (NVCR) Scheduled to Post Earnings on Thursday

NovoCure (NASDAQ:NVCR) will be releasing its earnings data before the market opens on Thursday, May 2nd. Analysts expect NovoCure to post earnings of ($0.42) per share for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link.

NovoCure (NASDAQ:NVCR) last posted its quarterly earnings results on Thursday, February 22nd. The medical equipment provider reported ($0.45) EPS for the quarter, topping the consensus estimate of ($0.53) by $0.08. The firm had revenue of $133.80 million for the quarter, compared to the consensus estimate of $133.80 million. NovoCure had a negative net margin of 40.65% and a negative return on equity of 51.63%. The business’s revenue was up 4.2% compared to the same quarter last year. During the same period last year, the firm posted ($0.36) earnings per share. On average, analysts expect NovoCure to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

NovoCure Trading Up 2.4 %

NVCR stock opened at $12.34 on Thursday. The company has a market capitalization of $1.33 billion, a PE ratio of -6.33 and a beta of 0.42. NovoCure has a one year low of $10.87 and a one year high of $83.60. The company’s 50 day moving average price is $14.57 and its two-hundred day moving average price is $13.94. The company has a debt-to-equity ratio of 1.57, a quick ratio of 5.56 and a current ratio of 5.78.

Insider Buying and Selling at NovoCure

In other NovoCure news, COO Wilhelmus Cm Groenhuysen sold 2,107 shares of the business’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $16.03, for a total transaction of $33,775.21. Following the transaction, the chief operating officer now directly owns 252,452 shares of the company’s stock, valued at approximately $4,046,805.56. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, EVP Frank X. Leonard sold 1,679 shares of the business’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $16.03, for a total transaction of $26,914.37. Following the sale, the executive vice president now owns 160,938 shares in the company, valued at approximately $2,579,836.14. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, COO Wilhelmus Cm Groenhuysen sold 2,107 shares of the business’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $16.03, for a total transaction of $33,775.21. Following the sale, the chief operating officer now owns 252,452 shares in the company, valued at approximately $4,046,805.56. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 7,921 shares of company stock valued at $127,161. 5.67% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several brokerages recently commented on NVCR. JPMorgan Chase & Co. lifted their target price on shares of NovoCure from $15.00 to $17.00 and gave the stock a “neutral” rating in a research note on Tuesday, March 19th. Wedbush reaffirmed a “neutral” rating and issued a $21.00 target price on shares of NovoCure in a research note on Wednesday, March 27th. Evercore ISI lifted their target price on shares of NovoCure from $14.00 to $15.00 and gave the stock an “in-line” rating in a research note on Friday, February 23rd. Wells Fargo & Company decreased their target price on shares of NovoCure from $49.00 to $42.00 and set an “overweight” rating on the stock in a research note on Wednesday, April 3rd. Finally, HC Wainwright lifted their target price on shares of NovoCure from $22.00 to $24.00 and gave the stock a “neutral” rating in a research note on Wednesday, March 27th. Five analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $31.13.

NovoCure Company Profile

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua.